A recent study in the USA has indicated potential advancements in treating aggressive brain tumors, specifically Glioblastoma.

Published in The New England Journal of Medicine, the study details a new CAR-T therapy that injects modified cells into the brain.

The Phase 1 clinical trial combined CAR-T cells with bispecific antibodies, targeting diverse cell populations within tumors.

Early results showed dramatic tumor reductions in the first three patients, although subsequent tumor progression was noted.

Ongoing research aims to improve the long-term efficacy of the therapy, with a call for more comprehensive trials.

This innovative approach could significantly alter the treatment landscape for Glioblastoma, a notably difficult cancer to treat.